ONCOLOGY journal

ONCOLOGY has been in publication for more than 30 years, earning a strong reputation as a reliable source of precise and high-quality information in this fast-changing field. Released every month, ONCOLOGY features reviews of the latest literature and treatment standards. It also includes sections such as: - Clinical Quandaries - How An Expert Approaches It - Comorbidity Consult - Point/Counterpoint

International, Trade/B2B

English

Journal

Outlet metrics

Domain Authority

Ranking

Global

#343294

United States

#116496

Health/Health

#2376

Traffic sources

Monthly visitors

Articles

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

2 days ago | cancernetwork.com | Tim Cortese

Thoracic radiotherapy twice daily at a dose of 60 Gy in 40 fractions prolonged survival and was well tolerated compared with a dose of 45 Gy in 30 fractions in patients with limited-stage small cell lung cancer (SCLC), according to a phase 2 trial (NCT02041845) published in the Journal of Thoracic Oncology.1Overall, the median overall survival (OS) was 33.3 months, with 34.1% of patients alive after 5 years.
High Response Rates Seen with Fruquintinib Combo in HER2- Advanced Gastric/GEJ Cancer

4 days ago | cancernetwork.com | Kyle Doherty

In the phase 2 FDZL-FIX trial (NCT06158919) trial, fruquintinib (Fruzaqla) with chemotherapy and PD-1 inhibition was evaluated as a frontline treatment for patients with HER2-negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and showed promising efficacy and an acceptable safety profile, according to results shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Six or More Cycles of Chemo Prolong Survival with Atezolizumab in ES-SCLC

4 days ago | cancernetwork.com | Tim Cortese

Receipt of 6 or more cycles of induction chemotherapy led to significantly prolonged progression-free survival (PFS) and overall survival (OS), enhancing the efficacy of first-line atezolizumab (Tecentriq) combined with chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC), according to results from a retrospective analysis published in Translational Lung Cancer Research.
EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

5 days ago | cancernetwork.com | Tim Cortese

The European Commission (EC) has approved brentuximab vedotin (Adcetris) in combination with ECADD—etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone—as a treatment for adult patients with newly diagnosed stage IIb with risk factors, stage III, and stage IV Hodgkin lymphoma, according to a press release from the developer, Takeda.1 Previously, in April 2025, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the combination for...
MagnetisMM-6 Data Suggest Safety, Manageability of Elranatamab Combo in NDMM

5 days ago | cancernetwork.com | Ariana Pelosci

Elranatamab-bcmm (Elrexfio) plus daratumumab (Darzalex) and lenalidomide (Revlimid; EDR) is safe and manageable for patients with transplant-ineligible multiple myeloma, according to results from the phase 3 MagnetisMM-6 Part 1 dose level G trial (NCT05623020), presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
FDA OKs Darolutamide in Metastatic Castration-Sensitive Prostate Cancer

5 days ago | cancernetwork.com | Tim Cortese

The FDA has approved darolutamide (Nubeqa) in the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC), according to a press release from the FDA.1 Previously, the FDA approved darolutamide combined with docetaxel in mCSPC.2 Supporting results from the approval came from the randomized phase 3 ARANOTE trial (NCT04736199) that evaluated the efficacy and safety of darolutamide vs placebo; all patients received a gonadotropin-releasing hormone analog concurrently or...
Daratumumab Plus KRd May Be a New SOC Option in NDMM

5 days ago | cancernetwork.com | Tim Cortese

Adding daratumumab (D; Darzalex) to carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) improved efficacy without compromising the known safety profile of all involved agents in the treatment of patients with newly diagnosed multiple myeloma, according to results from the phase 2 ADVANCE trial (NCT04268498) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 In the intention-to-treat population, the minimal residual disease (MRD) negativity...
Significant OS Benefit Observed With NAT Nivolumab/Chemo in Resectable NSCLC

5 days ago | cancernetwork.com | Kristi Rosa

A statistically significant and clinically meaningful overall survival (OS) benefit was observed when neoadjuvant novolumab (Opdivo) plus chemotherapy vs chemotherapy alone was used to treat patients with resectable non–small cell lung cancer (NSCLC), according to findings from the phase 3 CheckMate-816 study (NCT02998528) presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
SCRT/Chemo Produce Positive Responses in Locally Advanced Rectal Cancer

5 days ago | cancernetwork.com | Ariana Pelosci

Patients with medium to high locally advanced rectal cancer who received short-course radiotherapy (SCRT) followed by 1 cycle of folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and 7 cycles of folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI) had improved activity, according to results from the single-arm phase 2 ShorTrip trial (NCT05253846) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Neoadjuvant Osimertinib Enhances Responses in Resectable EGFR-Mutated NSCLC

5 days ago | cancernetwork.com | Kyle Doherty

Osimertinib (Tagrisso) monotherapy or with chemotherapy in the neoadjuvant setting displayed an major pathological response (MPR) rate advantage vs chemotherapy in patients with resectable EGFR-mutated non–small cell lung cancer (NSCLC), according to findings from the phase 3 NeoADAURA trial (NCT04351555) presented at the2025 American Society of Clinical Oncology (ASCO) Annual Meeting.